Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Anticancer agent 105, a thienopyrimidine scaffold-based compound, exhibits selective toxicity towards melanoma and induces apoptosis. Additionally, it significantly inhibits metastatic nodules, including in a pulmonary metastatic melanoma mouse model [1], while demonstrating good safety and anticancer properties.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Anticancer agent 105, a thienopyrimidine scaffold-based compound, exhibits selective toxicity towards melanoma and induces apoptosis. Additionally, it significantly inhibits metastatic nodules, including in a pulmonary metastatic melanoma mouse model [1], while demonstrating good safety and anticancer properties. |
In vitro | Anticancer agent 105 (compound 9cb) exhibits selectivity against cancer cells, demonstrating an IC50 of 2.41 μM for B16-F10 melanoma cells while exceeding 100 μM for normal, non-cancerous fibroblasts (MEF NF2) [1]. Additionally, this agent at concentrations ranging from 0.5 to 10 μM over 24 hours exhibits cytotoxic effects on cancer cells, and at 5 to 20 μM over 48 hours induces apoptosis and necrosis in B16-F10 cells [1]. |
In vivo | Anticancer agent 105 [compound 9cb] at a dosage of 9-9.5 mg/kg administered intraperitoneally every three days for a duration of 22 days, inhibited metastatic nodules in C57BL/6 mice bearing B16-F10 melanoma [1]. |
Molecular Weight | 533.64 |
Formula | C25H24KN3O6S |
CAS No. | 2450987-57-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Anticancer agent 105 2450987-57-0 Apoptosis inhibitor inhibit